Intraductal Carcinoma of the Prostate: A Guide for the Practicing Pathologist.
Journal
Advances in anatomic pathology
ISSN: 1533-4031
Titre abrégé: Adv Anat Pathol
Pays: United States
ID NLM: 9435676
Informations de publication
Date de publication:
01 Jul 2021
01 Jul 2021
Historique:
pubmed:
16
5
2021
medline:
13
7
2021
entrez:
15
5
2021
Statut:
ppublish
Résumé
Intraductal carcinoma of the prostate gland (IDCP) is characterized by an expansile, architecturally, and cytologically atypical proliferation of prostatic epithelial cells within preexisting prostatic ducts and acini. There has been a wider recognition of IDCP by practicing pathologists since its recognition as a separate category in the World Health Organization (WHO) 2016 classification of tumours of the prostate gland. However, there is also a lack of clarity regarding the diagnosis and reporting of IDCP, which has been compounded by divergent expert recommendations regarding the grading of invasive prostate cancers associated with an intraductal component. The International Society of Urological Pathologists (ISUP) recommends that the IDCP component should be incorporated into the Gleason score, while the Genitourinary Pathology Society (GUPS) recommends excluding it when grading prostate cancer. This review seeks to clarify some of these issues and outline a pragmatic approach to reporting IDCP, particularly in needle biopsies. Diagnostic issues and terminology for lesions falling short of IDCP but exceeding that of high-grade prostatic intraepithelial neoplasia are discussed. The management of patients whose prostate biopsies show only IDCP without an associated invasive component is controversial. Some experts recommend radical therapy, while others recommend prompt repeat biopsy. An alternative clinicopathologic approach that takes into consideration the extent, histomorphology, and location (with respect to a radiologic abnormality) of IDCP, as well as radiologic features, is outlined.
Identifiants
pubmed: 33990497
doi: 10.1097/PAP.0000000000000303
pii: 00125480-202107000-00007
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
276-287Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Chair Working Group on intraductal carcinoma and tumor growth patterns, ISUP (2019) consensus conference on the grading of prostatic carcinoma. M.V. has no funding or conflict of interest to disclose.
Références
Rhamy RK, Buchanan RD, Spalding MJ. Intraductal carcinoma of the prostate gland. J Urol. 1973;109:457–460.
Catalona WJ, Kadmon D, Martin SA. Surgical considerations in treatment of intraductal carcinoma of the prostate. J Urol. 1978;120:259–261.
Kovi J, Jackson MA, Heshmat MY. Ductal spread in prostatic carcinoma. Cancer. 1985;56:1566–1573.
McNeal JE, Reese JH, Redwine EA, et al. Cribriform adenocarcinoma of the prostate. Cancer. 1986;58:1714–1719.
McNeal JE, Yemoto CE. Spread of adenocarcinoma within prostatic ducts and acini. Morphologic and clinical correlations. Am J Surg Pathol. 1996;20:802–814.
Guo CC, Epstein JI. Intraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance. Mod Pathol. 2006;19:1528–1535.
Epstein JI, Oxley J, Ro JY, et al. Moch H, Humphrey PA, Ulbright TM, Reuter V. Tumours of the prostate: Intraductal carcinoma. WHO Classification of Tumours of the Urinary System and Male Genital Organs. Lyon, France: International Agency for Research on Cancer; 2016:164–165.
Miura N, Mori K, Mostafaei H, et al. The prognostic impact of intraductal carcinoma of the prostate: a systematic review and meta-analysis. J Urol. 2020;204:909–917.
Lawrence MG, Porter LH, Clouston D, et al. Knowing what’s growing: why ductal and intraductal prostate cancer matter. Sci Transl Med. 2020;12:eaaz0152.
Varma M, Delahunt B, Egevad L, et al. Intraductal carcinoma of the prostate: a critical re-appraisal. Virchows Arch. 2019;474:525–534.
Zhou M. High-grade prostatic intraepithelial neoplasia, PIN-like carcinoma, ductal carcinoma, and intraductal carcinoma of the prostate. Mod Pathol. 2018;31:S71–S79.
Divatia MK, Ro JY. Intraductal carcinoma of the prostate gland: recent advances. Yonsei Med J. 2016;57:1054–1062.
Wobker SE, Epstein JI. Differential diagnosis of intraductal lesions of the prostate. Am J Surg Pathol. 2016;40:e67–e82.
Tsuzuki T. Intraductal carcinoma of the prostate: a comprehensive and updated review. Int J Urol. 2015;22:140–145.
Magers M, Kunju LP, Wu A. Intraductal carcinoma of the prostate: morphologic features, differential diagnoses, significance, and reporting practices. Arch Pathol Lab Med. 2015;139:1234–1241.
van Leenders GJLH, van der Kwast TH, Grignon DJ, et al. The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. Am J Surg Pathol. 2020;44:e87–e99.
Epstein JI, Amin MB, Fine SW, et al. The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. Arch Pathol Lab Med. 2021;145:461–493.
Miyai K, Divatia MK, et al. Heterogeneous clinicopathological features of intraductal carcinoma of the prostate: a comparison between “precursor-like” and “regular type” lesions. Int J Clin Exp Pathol. 2014;7:2518–2526.
Robinson BD, Epstein JI. Intraductal carcinoma of the prostate without invasive carcinoma on needle biopsy: emphasis on radical prostatectomy findings. J Urol. 2010;184:132.
Delahunt B, Egevad L, Samaratunga H, et al. Intraductal carcinoma of the prostate is not a diagnostic entity. Histopathology. 2020;78:342–344.
Herawi M, Epstein JI. Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate. Am J Surg Pathol. 2007;31:889–894.
Bostwick DG, Cheng L, Meiers I Bostwick DG, Cheng L. Neoplasms of the prostate. Urological Surgical Pathology, 3rd ed. Philadelphia, PA: Saunders; 2014:409–531.
Cohen RJ, Wheeler TM, Bonkhoff H, et al. A proposal on the identification, histologic reporting, and implications of intraductal prostatic carcinoma. Arch Pathol Lab Med. 2007;131:1103–1109.
Aydin H, Zhang J, Samaratunga H, et al. Ductal adenocarcinoma of the prostate diagnosed on transurethral biopsy or resection is not always indicative of aggressive disease: implications for clinical management. BJU Int. 2010;105:476–480.
Shah RB, Yoon J, Liu G, et al. Atypical intraductal proliferation and intraductal carcinoma of the prostate on core needle biopsy: a comparative clinicopathological and molecular study with a proposal to expand the morphological spectrum of intraductal carcinoma. Histopathology. 2017;71:693–702.
Egevad L, Delahunt B, Kristiansen G, et al. Contemporary prognostic indicators for prostate cancer incorporating International Society of Urological Pathology recommendations. Pathology. 2018;50:60–73.
Varma M, Egevad L, Delahunt B, et al. Reporting intraductal carcinoma of the prostate: a plea for greater standardization. Histopathology. 2017;70:504–507.
Tolkach Y, Kristiansen G. Is high-grade prostatic intraepithelial neoplasia (HGPIN) a reliable precursor for prostate carcinoma? Implications for clonal evolution and early detection strategies. J Pathol. 2018;244:389–393.
Watts K, Li J, Magi-Galluzzi C, et al. Incidence and clinicopathological characteristics of intraductal carcinoma detected in prostate biopsies: a prospective cohort study. Histopathology. 2013;63:574–579.
Cohen RJ, Shannon BA, Weinstein SL. Intraductal carcinoma of the prostate gland with transmucosal spread to the seminal vesicle: a lesion distinct from high-grade prostatic intraepithelial neoplasia. Arch Pathol Lab Med. 2007;131:1122–1125.
Hickman RA, Yu H, Li J, et al. Atypical intraductal cribriform proliferations of the prostate exhibit similar molecular and clinicopathologic characteristics as intraductal carcinoma of the prostate. Am J Surg Pathol. 2017;41:550–556.
Haffner MC, Weier C, Xu MM, et al. Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization. J Pathol. 2016;238:31–41.
Morais CL, Han JS, Gordetsky J, et al. Utility of PTEN and ERG immunostaining for distinguishing high-grade PIN from intraductal carcinoma of the prostate on needle biopsy. Am J Surg Pathol. 2015;39:169–178.
Varma M, Alchami FS, Griffiths DFR. Retained basal cells in metastatic prostate cancer. Histopathology. 2016;69:338–340.
Porter LH, Lawrence MG, Ilic D, et al. Systematic review links the prevalence of intraductal carcinoma of the prostate to prostate cancer risk categories. Eur Urol. 2017;72:492–495.
Tom MC, Nguyen JK, Lucianò R, et al. Impact of cribriform pattern and intraductal carcinoma on Gleason 7 prostate cancer treated with external beam radiotherapy. J Urol. 2019;202:710–716.
Kato M, Tsuzuki T, Kimura K, et al. The presence of intraductal carcinoma of the prostate in needle biopsy is a significant prognostic factor for prostate cancer patients with distant metastasis at initial presentation. Mod Pathol. 2016;29:166–173.
Risbridger GP, Taylor RA, Clouston D, et al. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis. Eur Urol. 2015;67:496–503.
Gandhi JS, Smith SC, Paner GP, et al. Reporting practices and resource utilization in the era of intraductal carcinoma of the prostate: a survey of genitourinary subspecialists. Am J Surg Pathol. 2020;44:673–680.
Varma M, Epstein JI. Head to head: should the intraductal component of invasive prostate cancer be graded? Histopathology. 2021;78:231–239.
Khani F, Epstein JI. Prostate biopsy specimens with Gleason 3+3=6 and intraductal carcinoma: radical prostatectomy findings and clinical outcomes. Am J Surg Pathol. 2015;39:383–1389.
Shah RB, Nguyen JK, Przybycin CG, et al. Atypical intraductal proliferation detected in prostate needle biopsy is a marker of unsampled intraductal carcinoma and other adverse pathological features: a prospective clinicopathological study of 62 cases with emphasis on pathological outcomes. Histopathology. 2019;75:346–353.
National Comprehensive Cancer Network (NCCN). National Comprehensive Cancer Network prostate cancer guidelines; 17, 2021. Available at: www.nccn.org/professionals/physician_gls/pdf/prostate.pdf . Accessed March 20, 2021.
National Institute for Health and Care Excellence (NICE). National Institute for Health and Care Excellence guidelines for prostate cancer: diagnosis and management; 2019. Available at: www.nice.org.uk/guidance/ng131 . Accessed March 20, 2021.